Press Release: FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY(R) Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
Committee reviewed clinical data showing a booster dose of COMIRNATY(R)
elicits high neutralization titers against SARS-CoV-2 and all currently
Reactogenicity profile within seven days of the booster dose was
typically mild to moderate, with frequency of reactions similar to or
lower than after the primary vaccination series
Real-world data presented by Israel Ministry of Health show additional
protection after receiving a booster translated to vaccine effectiveness
comparable to levels seen early in the country's vaccine rollout
FDA expected to make its decision in the coming days
NEW YORK AND MAINZ, GERMANY, September 17, 2021Pfizer Inc. https://www.globenewswire.com/Tracker?data=FZHsHj_PKrGR9jM4TviKCpeRM7_Ljmm99ja6oA5Nz7hz32Xno_IlbZA4JlvEZhJsDxpoZ3N9ARNyEPGwqrwckg (NYSE: PFE) and BioNTech SE https://www.globenewswire.com/Tracker?data=6x1y5wt6AYmaRVmA07TlCEj_pd9Uh5vcqjKWu_ZhL8sHPFEvJSWU1pA5R_FDzIF0vvPwP4BI9Jlk2-FsL2LLXA (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY(R) (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.
VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.
At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.
The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.
Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "We thank the committee for their thoughtful review of the data and will work with the FDA following today's meeting to address the committee's questions, as we continue to believe in the benefits of a booster dose for a broader population."
We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need," said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.
VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.
Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine https://www.globenewswire.com/Tracker?data=y4ChjF8j_EX68huwoeTaM1hYspO_KWGoCm6_n7seU9yYoJG5iD2jOQzEWuxZy0tLxmbtwhg9ZfKf-v9gaHtGUGeYCHrLZzVA_gGGyKO5zrdP4q70XxIBUMOF74O2dvWuS8CTKGBU3C9nzLDtY3AA . The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country's vaccine rollout (an estimated 95%), when the Alpha variant was predominant.
Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was https://www.globenewswire.com/Tracker?data=IEUO2kpVrs9XIGSvTEOGmCBxFMtUzOpOk3dJ_sCP5sW9pO_MF89ExVcK6r_TS6d9k3DURrSA4FSMKWDJDdG3AxtYjUtYeO_o_xmwn_K2zCUlNwDO8m6Jw4lw5YW4ImHXpgNZQ64DF0-C8LHKWe9m7ESvr7zcJPCLj0mH8V5kI18EUOzvBfcbd5Ct5PoshFG6Ypj6D2dl0TfV7EYKnxjzxGP0hpPDPsX7cF5kHqRNFqd1GXBqXubouxKAIZhg5flC previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.
COMIRNATY, which is based on BioNTech's proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.
U.S. Indication & Authorized Use
COMIRNATY(R) (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.
It is approved as a 2-dose series for prevention of COVID-19 in
individuals 16 years of age and older
It is also authorized under Emergency Use Authorization (EUA) to be
administered for emergency use to:
prevent COVID-19 in individuals 12 through 15 years, and
provide a third dose to individuals 12 years of age and older who
have been determined to have certain kinds of immunocompromise
The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:
prevent COVID-19 in individuals 12 years of age and older, and
provide a third dose to individuals 12 years of age and older who have
been determined to have certain kinds of immunocompromise
The FDA-approved COMIRNATY(R) (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY(R) (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
Important Safety Information
Individuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:
had a severe allergic reaction after a previous dose of this vaccine
had a severe allergic reaction to any ingredient of this vaccine
(MORE TO FOLLOW) Dow Jones Newswires
September 18, 2021 03:40 ET ( 07:40 GMT)
Individuals should tell the vaccination provider about all of their medical conditions, including if they:
have any allergies
have had myocarditis (inflammation of the heart muscle) or pericarditis
(inflammation of the lining outside the heart)
have a fever
have a bleeding disorder or are on a blood thinner
are immunocompromised or are on a medicine that affects the immune system
are pregnant, plan to become pregnant, or are breastfeeding
have received another COVID-19 vaccine
have ever fainted in association with an injection
The vaccine may not protect everyone.
Side effects reported with the vaccine include:
There is a remote chance that the vaccine could cause a severe allergic
A severe allergic reaction would usually occur within a few
minutes to one hour after getting a dose of the vaccine. For this
reason, vaccination providers may ask individuals to stay at the
place where they received the vaccine for monitoring after
Signs of a severe allergic reaction can include difficulty
breathing, swelling of the face and throat, a fast heartbeat, a
bad rash all over the body, dizziness, and weakness
If an individual experiences a severe allergic reaction, they
should call 9-1-1 or go to the nearest hospital
Myocarditis (inflammation of the heart muscle) and pericarditis
(inflammation of the lining outside the heart) have occurred in some
people who have received the vaccine. In most of these people, symptoms
began within a few days following receipt of the second dose of the
vaccine. The chance of having this occur is very low. Individuals should
seek medical attention right away if they have any of the following
symptoms after receiving the vaccine:
shortness of breath
feelings of having a fast-beating, fluttering, or pounding heart
Side effects that have been reported with the vaccine include:
severe allergic reactions; non-severe allergic reactions such as
rash, itching, hives, or swelling of the face; myocarditis
(inflammation of the heart muscle); pericarditis (inflammation of
the lining outside the heart); injection site pain; tiredness;
headache; muscle pain; chills; joint pain; fever; injection site
swelling; injection site redness; nausea; feeling unwell; swollen
lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain
These may not be all the possible side effects of the vaccine. Serious
and unexpected side effects may occur. The vaccine is still being studied
in clinical trials. Call the vaccination provider or healthcare provider
about bothersome side effects or side effects that do not go away
There is no information on the use of the vaccine with other vaccines.
Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.globenewswire.com/Tracker?data=cqMoKZXGH82cJZP8ILzrrixE9H0PTNpl_1Xw4COIb0hneZCe9fld0g_4okfYf9FnPlKRu7I3TtSvplt7b08efIZugsM_sWG1H9Si-YMbWDVlYI5IL4zEcvMhEDpiRoxjUcyMYUDcHdJSyxH9uWHhuliAnE0lR9GtkPFM3Ltdmoma5yTSnFtZcPn_GtAFE8EGbXbqqpVsJ929QBF72PI-od4J8fokyUqZC1wu8w7sklTq1agoSuW0jYS-12T_5sO-_YeB266HBFd9srizV3DeOmJGk_1-uSIfR8LBeIenTqjhnugjE3aVUDvVRBwuHh20 http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBdXKEZ4M5_-IbN3yLxDwCyApKck_R48I91kwpzQeF7-aPCRkQhTuk_Zyo0VlGKjZ0eD_E9jwfkqrt4VhYjhqjZ1tkWuspEcuJfrDILH48H_AaxouqQxW2hvGkRCB3VryQKMa8MUfttm5txxkkRKnt8QMx1LOjPX9RXjIeP5PE-RLUTPcrWvEYpCcKK3q6PK5pFOU9JRy_R0DaETz_0zNee4yvjfNV7GZSLj54rTN82dHWSDVVLEcS2B1QQTly04ojQpHFgHHxuHdxb2zRLZnebIcNAk2i4fE5q6LkQkSdkRo3qtEKEdTcI1ThNQXS5j5ig www.pfizersafetyreporting.com or by calling 1-800-438-1985.
Please https://www.globenewswire.com/Tracker?data=ZlJrZ6h7-K8kRq_TUZQiR_iS3K8aU4XNVTUiNVTwOhL-ik1hQyFsNRUcJG67VAR-KgV-mhP8CvzNhwSIEA0QW8Nej8Oo5mAs2GHeN-_4BfdpS-h2csMBSNGFU2hWEFO26rn6_emTZUV0-HkVHp3ilyZQJlHUHG6_Dcxp_oyYmrfPbGHMkBTkB1UYSc4eGjEa1PYY50SFcjQeZxBNIdn4oh1GkAQ0YZQrEgS-YEpj421M05nHuLqrW13xEDAqXmuJDrtzl4BYN2iBFL5JgBngMVWrT7LjN-DqwEYKropIbLfjX9B9hTTtqN6OwHfav86TCSB3VyAX-T3ux63kO8yUOw click here for full Prescribing Information (16+ years of age). Please https://www.globenewswire.com/Tracker?data=ZlJrZ6h7-K8kRq_TUZQiR3-qIAoiHuvDPycWX4ohVTX49R1uMFnO5_OGKGr7nh7YaawMFl-vOQSsDb3COQgfeL0aZgIEf8FMroROEpGXCgxdg1lNXCRoimNuoQZpU4EoEwdLyzIQSlnlYthVfrJ43aN_-8mt9w5cM8Len2mq6dSw4eN5GaL-sudreSo4JXgJYcsg-dJGigVZJSuZFDF34Nny8mY7rCup2hm1qxbnnyIWffCP-Xhza9OFRxRDTOE_IekMwW006vweddyh1W185Q3SCVQFdR5xx1QebTESVvg8YYz4635Hp0Of2FUgxaGksZ9fvhaonoWcMFuo-agRNw click here for Fact Sheet for Vaccination Providers (12+ years of age).
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBW9HY3cmptuRyyOktWDFlbFicw16FTKTQ-CAr-CCkqHjVdJhqoQ6yKaBctwOU5tUx8L01cPvcl6q0PtN3iw61EmqSuWSpV6QgJPGFGajFvczzBaHbwpt76-9mXYcMBCECgQPFcrIXPKL4DdumJSrOV547flfgSXvoiIv7NgCE5g2luA8gvmQfOVTg-ilKtN2orFqRfmkidoFsPtULi0dkuZ9oW_j1koQPw0vjUwkdPA_i2kcD_v6-zQ_NXXNm5FBSAUgPcDtz3SeFqBMXCTGcLk= www.Pfizer.com. In addition, to learn more, please visit us on https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBZo1YzbxWpPPExN8kKi9MmHqNOfr9B0NVOf1zCVd9BOP0kRVVu91tPM7pyMZ5hS14ivfiNppy_Xq1NwIb6HQ4JwFo_JSTQGPStSdNJsKT0Xpxi0EyYfy3Xi9fUbRwx7Dp8MqljBzD8HzGD6-ts4MLG3CID8lxjfW_bGYnPkS0lBoOpB_EwLQpDt3nROdQt6XaZIeeJofV3Wq54GcLGD91oZrSdQXzEKcwCFaR6Y56lCyiZRbcEftqOLHbIMfqPNCvfZB0XJg-m8lFbdCFcu5igI= www.Pfizer.com and follow us on Twitter at https://www.globenewswire.com/Tracker?data=U4k7Xoa5gUH_SddaZhFYLLqh0mEuKEWYDZNcTamLQWtopmTNfpK0s-vVqPVNtevkGp5CSiiJFcA_2HI3uwjelZLCNEytOKbx1_IR7HDK_B2F9S3OiOkVso7LFdkBEDRS2NASQ3UNgm1bI5shq298NvQ3hrcc9Pk8orzMWn7g97xrYPG39-RDitgCzATZRC6LMgMPsVV81yjOaFUdjDS9BPR025z3crHFHWY-XCPNa0OnrXJsnbQM7ZTavhUYWGO9d4BowO8L26grQD_1u4kYng @Pfizer and https://www.globenewswire.com/Tracker?data=U4k7Xoa5gUH_SddaZhFYLPe6fViBJs5lk2fHVXVg-UUbDrgMzM__2Wsrs7GZYSCziQGt02Hma_FOE-PjhPueaAwQRgbtqVl_qmglWcrMKc5zkOEon_egYxJWnKJyIxDNjDW1E8QtkVouavEed9I597Jp3vH8sVrN2ePydeW126oPypQHQ-GkNpL4x5Nhp4hjpXrj9FSlnS-YDT6odQ83oh01ekUHIpStCj1uU7bCmnq4jXPuPMMfGXNwJeNG__XS7Jl6RSdcWryDwQ5VXPOvhYPnNEwlopUZ-Hu0T6OTP9U= @Pfizer News, https://www.globenewswire.com/Tracker?data=yjB8pDe3eZ6QqRFMxqohhpJjgTRQRQDARUlVRTrBY6sI_CoEVAVhMy6Iy1vWVlJLuvboMvaoqsBvlfxDkoQYZUpkSEOBRA1NLS5M3LEmEGEH3hRqdzLeXZAMSOx5l9-uwZcUqMQp6IjZCJ52Y30xpoFZz0h-l2QKunG7ayNy6c9Jo3fe9um73H6ggF018Lv3iZAVJmTwp-tq20SQ4n_-_KiDHIMF1jUV0eGUJjWvseKoZ7O8wbBc2AVaUKsJpAuvbSWA3ax-svX5UOMqCVMojmCt9VGCU1hVZto-hYJh2sI= LinkedIn, https://www.globenewswire.com/Tracker?data=Zt6JCFMAgE2O99P0HZsnpsWbfn3uH5l8B_vUP7NkJfdcgvbDsVirndAO-s3tu9natCMtODbyhI5Lsxvee3gMgC7M_KrxycKQNDKuTUqwqgG0AHIc7eGTBvaVOhg9SfKJy1XejD8EMC_Yw7DPq2vSGqkdWmMRi8wjob7BJeP7PChbwcupP1nGSnrMPehVWe5lp8NHLqPJxhouO1VixbiheqPSwtQnbkL7PiEox34z03HnTXPGXlyrVVWed6BY0Opmc0oNoeiTv3qVOqQ6MLD0aF92y2UPL0eMpPev8iL_aSU= YouTube and like us on Facebook at https://www.globenewswire.com/Tracker?data=vSuEsC59M97PG99MgkAADWrnUyDp1YgxHNv_f1v6ylPR6xaai7egb_Lr-DKEl5977-82voU9tA3HcoymsC8XNx5PVLl5GaPguAXEAq_-QZv61jifXxM6AGOAVBjn7a9oQVgWnIyRp7Ad1i-WKk1KrvCjb_bOcIcljg7C2ozuC7BP7g7wxgEbko1qo1zqJNMQXtVGsdLE9689GUnTN6F9AQ5_-ua3mGkqr9G-ZthcAsE-ul2uItFzhlEziWfagjW4BwFoYFdldOBkPcCC1ugvsrwqTMU6G8jWk1M_djZtIofn7cL3QrD4W5tDpkaqX4Tg Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer's efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical
MORE TO FOLLOW) Dow Jones Newswires
September 18, 2021 03:40 ET ( 07:40 GMT)
Press Release: FDA Advisory Committee Votes -2-
| Quelle: Dow Jones Newsw... | Lesedauer etwa 12 min. | Text vorlesen Stop Pause Fortsetzen
Das könnte Sie auch interessieren
Im Artikel erwähnt...
|Porträt - Chart - Firmenprofil|
Meistgelesenweitere oft gelesene Nachrichten
Aktuelle Videoszur Mediathek
Diese Seite empfehlenschliessen
Teilen Sie diese Seite auf Facebook oder Twitter
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 48 - stehen?